Skip to content

Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy

Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00803725
Enrollment
34
Registered
2008-12-05
Start date
2008-08-31
Completion date
2009-05-31
Last updated
2010-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Arthroscopy

Keywords

spinal anesthesia, mepivacaine, fentanyl, duration of anesthesia, knee arthroscopy, regional anesthesia, Spinal anesthesia for knee arthroscopy

Brief summary

The purpose of this study is to determine if the addition of intrathecal fentanyl to low dose mepivacaine spinal anesthesia provides adequate surgical anesthesia with shorter duration of motor blockade. It is hypothesized that lower doses of spinal mepivacaine when combined with fentanyl will result in adequate surgical block for knee arthroscopy surgery with faster recovery and discharge compared to mepivacaine alone.

Interventions

DRUGMepivacaine without fentanyl

45 mg 1.5% mepivacaine injection for spinal anesthesia

DRUGMepivacaine with Fentanyl

10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia

Sponsors

University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Patients having unilateral arthroscopic surgery of the knee; 2. ASA I-III status; 3. Age 18-80 years; 4. BMI\< 35.

Exclusion criteria

1. Patients who have previous history of hypersensitivity to local anesthetics or contraindications for spinal anesthesia (i.e. bleeding diathesis, coagulopathy); 2. Patients with radiating low back pain and neurological deficits in lower extremities; 3. Patients who are incapable of giving an informed consent.

Design outcomes

Primary

MeasureTime frame
Time to complete motor block regression (0) as measured by modified Bromage scale.Every 2 minutes from administration of the spinal until complete onset.

Secondary

MeasureTime frame
Block success, peak, and duration; time to ambulation, urination, discharge; incidence of adverse events.Up to 72 hours after surgery.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026